Form Bio, an AI-powered genetic medicine and genome engineering firm, has appointed Michelle Chen, Ph.D., as its president, chief executive officer, and director, according to the company. She succeeds co-founders Andrew Busey and Kent Wakeford, who will remain involved as strategic advisors and executive chairs of the board.
The company said that Dr. Chen brings more than 25 years of leadership experience in therapeutics, AI-driven drug discovery, biotech and global pharmaceuticals. She most recently served as chief business officer at Insilico Medicine, where she supported significant fundraising, business development, and advancement of assets to the clinical stage. Her previous roles include senior leadership positions at WuXi Biologics, Roche, Merck & Co., BioMarin, Agilent Technologies, and Applied Biosystems.
According to the company, Form Bio has rapidly become a trusted AI-native partner to gene therapy developers since spinning out from Colossal Biosciences in 2022. The company claims that with Dr. Chen’s appointment, it will further expand global operations, deepen research and development investment, and enhance leadership in delivering AI-powered in silico tools that accelerate discovery and improve genome-based therapeutic design.
